UTI AMC Q1 FY27 Results: Board Meet on July 22

Board meeting set for July 22, 2026

UTI Asset Management Company (UTI AMC) has scheduled a board meeting on July 22, 2026, to approve its Q1 FY27 financial results. The date matters because the company has seen sharp swings in profitability over the last few reported quarters, including a loss in the March 2026 quarter after a period of profits. For investors, the upcoming update is also the first full-quarter result cycle after the recent CEO transition earlier in 2026. UTI AMC’s market snapshot in the provided data shows a market capitalisation of ₹12,016.45 crore and a CMP of ₹934.95.

What the company has disclosed about the agenda

The disclosed agenda point is straightforward: approval of the Q1 FY27 results at the July 22 board meeting. No additional items such as dividend declaration or corporate actions are specified for this meeting in the provided details. The focus, therefore, is likely to remain on quarterly operating performance, profitability, and any commentary on flows and assets under management.

Leadership change: new MD and CEO from February 2026

A key organisational change ahead of FY27 is the leadership transition at the top. Mr. Vetri Subramaniam took over as Managing Director and CEO effective February 1, 2026, succeeding Mr. Imtaiyazur Rahman. This change is relevant for investors tracking strategic priorities, cost control, and distribution mix, especially in an asset management business where market share and flows can shift quickly.

Recent quarterly performance: profit volatility and a March 2026 loss

The data provided points to a difficult patch in the quarter ended March 31, 2026. The company posted a loss of ₹66.71 crore for that quarter (source stated as consolidated financials), after three consecutive quarters of profits. Separately, the “Quick Details” section lists the previous quarter revenue at ₹331 crore and PAT at ₹34 crore, serving as a reference point for sequential comparisons going into Q1 FY27.

The broader quarterly table included in the text also highlights strain around March 2026, showing operating profit at -₹12 crore and profit before tax at -₹17 crore for that quarter, along with a negative EPS of -₹5.19. Taken together, the numbers underscore why the July 22 result update will be closely watched for any stabilisation in earnings.

FY26 snapshot: dividend and audited results cycle

UTI AMC announced FY26 financial results with standalone PAT of ₹460 crore and recommended a final dividend of ₹40 per share. The company had also scheduled a board meeting on April 23, 2026, to approve audited standalone and consolidated financial results for Q4 FY26 and FY26, along with dividend recommendations. An earnings conference call was held on April 23, 2026 at 1800 hrs IST on the company’s performance for the quarter and year ended March 31, 2026.

This FY26 context is important because it links the March-quarter volatility with the full-year payout decision. It also sets a baseline for what investors may expect in terms of capital return policy, subject to shareholder approval at the AGM for the final dividend.

Earlier FY26 quarters: mixed profit trend despite revenue growth

The provided data includes several FY26 quarterly reference points. For Q3 FY26, UTI AMC reported net profit of ₹123.68 crore, down 13% from ₹142.49 crore in Q3 FY25, while revenue grew 28% to ₹423.12 crore. For Q2 FY26 (consolidated highlights), core income (sale of services) was ₹390 crore, core PAT was ₹107 crore, and PAT was ₹113 crore.

For Q1 FY26, UTI AMC reported consolidated revenue from operations of ₹547 crore and consolidated PAT of ₹237 crore, while total group AUM stood at ₹21,93,215 crore. The company also reported SIP-related metrics for Q1 FY26, including gross SIP inflow of ₹2,260.98 crore and SIP AUM of ₹42,195.93 crore as of quarter end.

Share price references and market snapshot

The text includes two price reference points for the stock. It states UTI AMC share price was ₹940.70 as on May 29, 2026 (03:53 PM IST), down 1.20% from the previous share price of ₹952.75. The “Quick Details” section lists the CMP at ₹934.95 and market cap at ₹12,016.45 crore.

These datapoints provide context for how the market has been pricing the stock ahead of the Q1 FY27 board meeting, especially after the March 2026 loss and the FY26 dividend announcement.

Key figures at a glance

Market impact and what investors will watch on July 22

The July 22 meeting is important because recent disclosures show sharp profit compression in some quarters and a loss in March 2026. Investors typically look for clarity on whether the loss was driven by one-off items, market-linked impacts, or cost pressures, and whether core profitability has normalised. Given the company’s disclosed focus areas in prior periods such as SIP inflows, folio additions, and market share in gross sales, readers will likely watch for updates on asset mix and flow trends as well.

From a market perspective, the stock’s price references around ₹935 to ₹941 provide a near-term anchor going into the result event. Any deviation in Q1 FY27 revenue, PAT, and core income versus the immediately preceding reference quarter (revenue ₹331 crore, PAT ₹34 crore in the provided “previous quarter” snapshot) will shape the initial reaction.

Conclusion

UTI AMC’s board will meet on July 22, 2026, to approve Q1 FY27 results, with attention on earnings stability after a March 2026 quarterly loss and the FY26 dividend recommendation of ₹40 per share. The next update will also be read in the context of the leadership change effective February 1, 2026, and the company’s recent disclosures on AUM, SIP metrics, and quarterly profit movement.